# Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy

> **NCT05643417** · PHASE1 · UNKNOWN · sponsor: **Fudan University** · enrollment: 80 (estimated)

## Conditions studied

- Metastatic Liver Cancer

## Interventions

- **DRUG:** HAIC、Bevacizumab、Camrelizumab

## Key facts

- **NCT ID:** NCT05643417
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12
- **Primary completion:** 2023-10
- **Final completion:** 2024-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05643417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05643417, "Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05643417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*